Crisugabalin provides significant improvement in average daily pain score and shows promise as a postherpetic neuralgia treatment.

Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 clinical study, ...

Pregabalin is indicated for fibromyalgia and pain associated with diabetic peripheral neuropathy or spinal cord injury, in ...

The Phase III trial AV001 aims to evaluate QUTENZA in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...

Many Brits might unknowingly be walking a knife’s edge with their health, as an expert warned if left untreated, the disease ...

Many Brits could be unknowingly teetering on the brink of serious health issues, as a leading expert warns that if left ...

The potential benefits of GTx-104 in the treatment of aSAH will be highlighted in our Key ... bupivacaine spray designed to ease the symptoms of patients suffering with postherpetic neuralgia (PHN).

Pregabalin has demonstrated efficacy in the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic ... may be beneficial for the treatment of neuropathic ...

Gabapentin is a prescription medication that was approved by the U.S. Food and Drug Administration in 1993 as a treatment for epilepsy ... and to diminish a specific type of nerve pain called ...